Holen Sie sich die Stockscreener-App
31.12
4.33%
-1.41
Schlusskurs vom Vortag:
$32.53
Offen:
$32.72
24-Stunden-Volumen:
1.42M
Relative Volume:
1.13
Marktkapitalisierung:
$3.71B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-10.77
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
-3.68%
1M Leistung:
+0.91%
6M Leistung:
-30.88%
1J Leistung:
+116.26%
1-Tages-Spanne:
$31.06
$33.21
1-Wochen-Bereich:
$31.06
$33.37
52-Wochen-Spanne:
$13.73
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
31.12 | 3.71B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences Announces Inducement Grants -February 21, 2025 at 05:50 pm EST - Marketscreener.com
Biotech Talent Wars: Avidity Secures 22 Key Hires With Million-Dollar Equity Package - StockTitan
Avidity Biosciences (RNA) Projected to Post Earnings on Wednesday - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Buy" by Analysts - MarketBeat
(RNA) Proactive Strategies - Stock Traders Daily
Legato Capital Management LLC Invests $301,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 7%Here's Why - MarketBeat
abrdn plc Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 5,875 Shares - MarketBeat
(RNA) Investment Report - Stock Traders Daily
RNA Drug Development Pioneer Joins Codexis: Oligonucleotide Expert Who Created First Approved Antisense Drugs - StockTitan
Avidity Biosciences chief program officer sells $188,918 in stock - MSN
Avidity Biosciences chief program officer sells $188,918 in stock By Investing.com - Investing.com UK
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely - Yahoo Finance
How to Take Advantage of moves in (RNA) - Stock Traders Daily
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6%Here's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Avidity Biosciences CEO Sarah Boyce sells $297k in stock - MSN
Avidity Biosciences' chief medical officer sells shares totaling $112,856 - MSN
Assenagon Asset Management S.A. Invests $1.18 Million in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock - MSN
Avidity Biosciences chief scientific officer sells shares worth $162,191 - MSN
Avidity Biosciences director sells $53,536 in stock - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 3,287 Shares - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 2,959 Shares of Stock - MarketBeat
Sarah Boyce Sells 10,397 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock By Investing.com - Investing.com Canada
Arthur A. Levin Sells 1,872 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences director sells $53,536 in stock By Investing.com - Investing.com Canada
Avidity Biosciences CFO sells $93,985 in stock By Investing.com - Investing.com Canada
Avidity Biosciences chief program officer sells shares worth $206,799 By Investing.com - Investing.com Canada
Avidity Biosciences chief program officer sells shares worth $206,799 - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $297k in stock By Investing.com - Investing.com UK
Avidity Biosciences' chief medical officer sells shares totaling $112,856 By Investing.com - Investing.com UK
Analysts Offer Predictions for RNA FY2025 Earnings - MarketBeat
Leerink Partnrs Has Negative Estimate for RNA Q1 Earnings - MarketBeat
Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Exciting News from Avidity Biosciences! New Opportunities Await! - qhubo.com.ni
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avidity Biosciences Inc-Aktie (RNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
Feb 03 '25 |
Sale |
32.16 |
5,875 |
188,918 |
50,554 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):